TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC

Lou,Ming; Gao,Zhaojia; Zhu,Tao; Mao,Xiaoliang; Wang,Yeming; Yuan,Kai; Tong,Jichun

doi:10.3892/ol.2019.11199

TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC

Authors:
- Ming Lou
- Zhaojia Gao
- Tao Zhu
- Xiaoliang Mao
- Yeming Wang
- Kai Yuan
- Jichun Tong
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, P.R. China, Department of Thoracic Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, P.R. China
Published online on: December 10, 2019 https://doi.org/10.3892/ol.2019.11199
Pages: 1400-1408
Copyright: © Lou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a member of the tripartite motif family, tripartite motif‑containing protein 59 (TRIM59) serves as an E3 ubiquitin ligase in various cellular processes, including intracellular signaling, development, apoptosis, protein quality control, innate immunity, autophagy and carcinogenesis. The present study aimed to investigate the expression and prognostic value of TRIM59 in patients with non‑small cell lung cancer (NSCLC). Expression of TRIM59 in patients with NSCLC was measured by immunohistochemistry in tissue microarrays. Datasets from The Cancer Genome Atlas (TCGA) were used to further verify the expression level of TRIM59 in NSCLC, lung adenocarcinoma and lung squamous cell carcinoma (LUSC). The prognostic value of TRIM59 in NSCLC was also analyzed. Immunohistochemistry revealed that TRIM59 was primarily located in the cytoplasm of tumor cells. Analysis of TCGA datasets revealed that TRIM59 was more highly expressed in tumor tissues than in normal tissues (P<0.0001). Furthermore, the TRIM59 expression level was associated with tumor differentiation (P=0.012), while no association was observed between TRIM59 expression and any other clinicopathological parameters. However, the average overall survival rate of patients with NSCLC in the high TRIM59 expression group was significantly lower than that in the low expression group (P=0.014), especially in patients with LUSC (P=0.016) and patients with poor differentiation (P=0.033). The multivariate analysis indicated that high TRIM59 expression is an independent prognostic factor in patients with NSCLC (P=0.018) and was associated with poor prognosis in patients with NSCLC. Therefore, TRIM59 may serve as a novel molecular biomarker to predict the prognosis of patients with NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Hoffman RM and Sanchez R: Lung cancer screening. Med Clin North Am. 101:769–785. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Zeng H and Zhang S: Epidemiology of lung cancer in China. Thorac Cancer. 6:209–215. 2015. View Article : Google Scholar : PubMed/NCBI
4	Sun KX, Zheng RS, Zeng HM, Zhang SW, Zou XN, Gu XY, Xia CF, Yang ZX, Li H, Chen WQ and He J: The incidence and mortality of lung cancer in China, 2014. Zhonghua Zhong Liu Za Zhi. 40:805–811. 2018.(In Chinese). PubMed/NCBI
5	Mengoli MC, Longo FR, Fraggetta F, Cavazza A, Dubini A, Alì G, Guddo F, Gilioli E, Bogina G, Nannini N, et al: The 2015 world health organization classification of lung tumors: New entities since the 2004 classification. Pathologica. 110:39–67. 2018.PubMed/NCBI
6	Hirsch FR, Suda K, Wiens J and Bunn PA Jr: New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
7	Li CY, Xiong DD, Huang CQ, He RQ, Liang HW, Pan DH, Wang HL, Wang YW, Zhu HW and Chen G: Clinical value of miR-101-3p and biological analysis of its prospective targets in breast cancer: A study based on the cancer genome atlas (TCGA) and bioinformatics. Med Sci Monit. 23:1857–1871. 2017. View Article : Google Scholar : PubMed/NCBI
8	Ikeda K and Inoue S: TRIM proteins as RING finger E3 ubiquitin ligases. Adv Exp Med Biol. 770:27–37. 2012. View Article : Google Scholar : PubMed/NCBI
9	Hatakeyama S: TRIM family proteins: Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
10	Rajsbaum R, Garcia-Sastre A and Versteeg GA: TRIMmunity: The roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol. 426:1265–1284. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chen W, Zhao K, Miao C, Xu A, Zhang J, Zhu J, Su S and Wang Z: Silencing Trim59 inhibits invasion/migration and epithelial-to-mesenchymal transition via TGF-β/Smad2/3 signaling pathway in bladder cancer cells. Onco Targets Ther. 10:1503–1512. 2017. View Article : Google Scholar : PubMed/NCBI
12	Liu Y, Dong Y, Zhao L, Su L, Diao K and Mi X: TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway. Mol Carcinog. 57:1792–1802. 2018. View Article : Google Scholar : PubMed/NCBI
13	Lin WY, Wang H, Song X, Zhang SX, Zhou PS, Sun JM and Li JS: Knockdown of tripartite motif 59 (TRIM59) inhibits tumor growth in prostate cancer. Eur Rev Med Pharmacol Sci. 20:4864–4873. 2016.PubMed/NCBI
14	Zhang Y and Yang WB: Down-regulation of tripartite motif protein 59 inhibits proliferation, migration and invasion in breast cancer cells. Biomed Pharmacother. 89:462–467. 2017. View Article : Google Scholar : PubMed/NCBI
15	Gao R, Lv G, Zhang C, Wang X and Chen L: TRIM59 induces epithelial-to-mesenchymal transition and promotes migration and invasion by PI3K/AKT signaling pathway in medulloblastoma. Oncol Lett. 15:8253–8260. 2018.PubMed/NCBI
16	Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, et al: Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 32:644–652. 2014. View Article : Google Scholar : PubMed/NCBI
17	Jin Y, Chen M and Yu X: Comparison of the 7(th) and proposed 8(th) editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery. Sci Rep. 6:335872016. View Article : Google Scholar : PubMed/NCBI
18	Gao ZJ, Wang Y, Yuan WD, Yuan JQ and Yuan K: HIF-2α not HIF-1α overexpression confers poor prognosis in non-small cell lung cancer. Tumour Biol. 39:10104283177096372017. View Article : Google Scholar : PubMed/NCBI
19	Li XR, Ji F, Ouyang J, Wu W, Qian LY and Yang KY: Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol. 32:1130–1134. 2006. View Article : Google Scholar : PubMed/NCBI
20	Xu H, Yu S, Yuan X, Xiong J, Kuang D, Pestell RG and Wu K: DACH1 suppresses breast cancer as a negative regulator of CD44. Sci Rep. 7:43612017. View Article : Google Scholar : PubMed/NCBI
21	Esposito D, Koliopoulos MG and Rittinger K: Structural determinants of TRIM protein function. Biochem Soc Trans. 45:183–191. 2017. View Article : Google Scholar : PubMed/NCBI
22	Micale L, Chaignat E, Fusco C, Reymond A and Merla G: The tripartite motif: Structure and function. Adv Exp Med Biol. 770:11–25. 2012. View Article : Google Scholar : PubMed/NCBI
23	Streich FC Jr, Ronchi VP, Connick JP and Haas AL: Tripartite motif ligases catalyze polyubiquitin chain formation through a cooperative allosteric mechanism. J Biol Chem. 288:8209–8221. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ozato K, Shin DM, Chang TH and Morse HC III: TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 8:849–860. 2008. View Article : Google Scholar : PubMed/NCBI
25	McNab FW, Rajsbaum R, Stoye JP and O'Garra A: Tripartite- motif proteins and innate immune regulation. Curr Opin Immunol. 23:46–56. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chan E, Towers GJ and Qasim W: Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses. 6:243–263. 2014. View Article : Google Scholar : PubMed/NCBI
27	Tomar D and Singh R: TRIM family proteins: Emerging class of RING E3 ligases as regulator of NF-κB pathway. Biol Cell. 107:22–40. 2015. View Article : Google Scholar : PubMed/NCBI
28	Gushchina LV, Kwiatkowski TA, Bhattacharya S and Weisleder NL: Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 185:12–25. 2018. View Article : Google Scholar : PubMed/NCBI
29	Han T, Guo M, Gan M, Yu B, Tian X and Wang JB: TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1. Autophagy. 14:2035–2048. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH and Gao WQ: TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology. 147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
31	Watanabe M and Hatakeyama S: TRIM proteins and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
32	Song X, Fu C, Yang X, Sun D, Zhang X and Zhang J: Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer. Oncol Lett. 10:2283–2288. 2015. View Article : Google Scholar : PubMed/NCBI
33	Dai HY, Ma Y, Da Z and Hou XM: Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer. Pathol Res Pract. 214:1130–1135. 2018. View Article : Google Scholar : PubMed/NCBI
34	Luo Q, Lin H, Ye X, Huang J, Lu S and Xu L: Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway. Int J Clin Oncol. 20:508–517. 2015. View Article : Google Scholar : PubMed/NCBI
35	Chen G, Chen W, Ye M, Tan W and Jia B: TRIM59 knockdown inhibits cell proliferation by down-regulating the Wnt/β-catenin signaling pathway in neuroblastoma. Biosci Rep. 39(pii): BSR201812772019. View Article : Google Scholar : PubMed/NCBI
36	Liang J, Xing D, Li Z, Shen J, Zhao H and Li S: TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma. Mol Med Rep. 13:5200–5206. 2016. View Article : Google Scholar : PubMed/NCBI
37	Sun Y, Ji B, Feng Y, Zhang Y, Ji D, Zhu C, Wang S, Zhang C, Zhang D and Sun Y: TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway. Oncol Rep. 38:43–52. 2017. View Article : Google Scholar : PubMed/NCBI
38	Valiyeva F, Jiang F, Elmaadawi A, Moussa M, Yee SP, Raptis L, Izawa JI, Yang BB, Greenberg NM, Wang F and Xuan JW: Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models. Mol Cancer Ther. 10:1229–1240. 2011. View Article : Google Scholar : PubMed/NCBI
39	Khatamianfar V, Valiyeva F, Rennie PS, Lu WY, Yang BB, Bauman GS, Moussa M and Xuan JW: TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis. BMJ Open. 2(pii): e0014102012. View Article : Google Scholar : PubMed/NCBI
40	Zhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M and Wang JB: TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI